Abstract
Introduction Covid-19 vaccines can cause adverse events (AE) that can lead to increased hesitation or fear of vaccination. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals (HPs) vaccinated with COVISHIELD™ vaccine in Togo.
Methods A cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among HPs who received the first dose of vaccine. An online self-administered questionnaire was used to collect data on sociodemographic characteristics and vaccination. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Regression analysis were performed to assess factors associated with SAEs.
Results A total of 1,639 HP (70.2% male) with a median age [IQR] of 32 years [27-40] participated. At least one AE was reported among 71.6% (95%CI= [69.3-73.8]). The most commonly reported AEs were pain at the injection site (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido was also reported in 3.0% of HP. Among HP who experienced AEs, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. The SAE prevalence was 23.8% (95%CI= [21.8-25.9]). Being <30 years (aOR=5.54; p<0.001), or 30-49 years (aOR=3.62; p<0.001) and being female (aOR=1.97; p<0.001) were associated with SAEs.
Conclusion Despite the occurrence of SAEs, current data collected in Togo about adverse events are reassuring with COVISHIELD™ vaccine and how they could be managed.
Key points
The prevalence of severe adverse events (SAEs) after COVID-19 vaccination was high among health professionals in Togo, especially in the youths (under 30years).
Despite the occurrence of SAEs, current data collected in Togo about adverse events are reassuring with COVISHIELD(TM) vaccine and provide information about how the could be managed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Bioethics Committee for Health Research from the Togo Ministry of Health (No. 01/2021/CBRS).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available on request to the corresponding author.
